Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis.
<h4>Objectives</h4>To assess the potential immunological and virological effects that result from short-course antiretroviral treatment during primary HIV infection (PHI). And to investigate whether treatment initiation time, treatment duration and follow-up time after treatment interrup...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24324793/?tool=EBI |
| _version_ | 1818338040322457600 |
|---|---|
| author | Jingjing Chen Xiaoxu Han Minghui An Jing Liu Junjie Xu Wenqing Geng Yangtao Ji Hong Shang |
| author_facet | Jingjing Chen Xiaoxu Han Minghui An Jing Liu Junjie Xu Wenqing Geng Yangtao Ji Hong Shang |
| author_sort | Jingjing Chen |
| collection | DOAJ |
| description | <h4>Objectives</h4>To assess the potential immunological and virological effects that result from short-course antiretroviral treatment during primary HIV infection (PHI). And to investigate whether treatment initiation time, treatment duration and follow-up time after treatment interruption would affect these post-treatment immunovirological outcomes.<h4>Methods</h4>We systematically searched PubMed, Cochrane Library (to September 2013) and retrieved conference abstracts for studies regarding effects of early treatment during PHI on CD4 count and viral load (VL). Using the method of calculating weighted mean differences with Stata11.0, we conducted meta-analyses on the effect of early treatment on CD4 count and VL. Then we performed subgroup analyses by follow-up time after treatment interruption, treatment initiation time and treatment duration. Baseline immunovirological characteristics were also analyzed to account for potential bias.<h4>Results</h4>Compared to the untreated arm, treatment during PHI not only increased CD4 count by 85.92 cells/μl but also lowered viral load by 0.30 log copies/ml within one year after treatment interruption. However, the benefits declined gradually, reaching no significance 12-24 months after treatment interruption. Baseline immunovirological characteristics and sensitivity analyses of randomized controlled trials indicated that the benefits mentioned above were underestimated. Extending treatment duration beyond 12 months did not increase efficacy.<h4>Conclusions</h4>Short-course treatment during PHI was associated with immunological and virological benefits which last for at least one year after treatment interruption. The conclusions from our study would help the decision-making in the clinical management of PHI. |
| first_indexed | 2024-12-13T15:04:47Z |
| format | Article |
| id | doaj.art-5a2d4bd59b7a4a3698c4833697c641db |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T15:04:47Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-5a2d4bd59b7a4a3698c4833697c641db2022-12-21T23:41:01ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8246110.1371/journal.pone.0082461Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis.Jingjing ChenXiaoxu HanMinghui AnJing LiuJunjie XuWenqing GengYangtao JiHong Shang<h4>Objectives</h4>To assess the potential immunological and virological effects that result from short-course antiretroviral treatment during primary HIV infection (PHI). And to investigate whether treatment initiation time, treatment duration and follow-up time after treatment interruption would affect these post-treatment immunovirological outcomes.<h4>Methods</h4>We systematically searched PubMed, Cochrane Library (to September 2013) and retrieved conference abstracts for studies regarding effects of early treatment during PHI on CD4 count and viral load (VL). Using the method of calculating weighted mean differences with Stata11.0, we conducted meta-analyses on the effect of early treatment on CD4 count and VL. Then we performed subgroup analyses by follow-up time after treatment interruption, treatment initiation time and treatment duration. Baseline immunovirological characteristics were also analyzed to account for potential bias.<h4>Results</h4>Compared to the untreated arm, treatment during PHI not only increased CD4 count by 85.92 cells/μl but also lowered viral load by 0.30 log copies/ml within one year after treatment interruption. However, the benefits declined gradually, reaching no significance 12-24 months after treatment interruption. Baseline immunovirological characteristics and sensitivity analyses of randomized controlled trials indicated that the benefits mentioned above were underestimated. Extending treatment duration beyond 12 months did not increase efficacy.<h4>Conclusions</h4>Short-course treatment during PHI was associated with immunological and virological benefits which last for at least one year after treatment interruption. The conclusions from our study would help the decision-making in the clinical management of PHI.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24324793/?tool=EBI |
| spellingShingle | Jingjing Chen Xiaoxu Han Minghui An Jing Liu Junjie Xu Wenqing Geng Yangtao Ji Hong Shang Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis. PLoS ONE |
| title | Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis. |
| title_full | Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis. |
| title_fullStr | Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis. |
| title_full_unstemmed | Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis. |
| title_short | Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis. |
| title_sort | immunological and virological benefits resulted from short course treatment during primary hiv infection a meta analysis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24324793/?tool=EBI |
| work_keys_str_mv | AT jingjingchen immunologicalandvirologicalbenefitsresultedfromshortcoursetreatmentduringprimaryhivinfectionametaanalysis AT xiaoxuhan immunologicalandvirologicalbenefitsresultedfromshortcoursetreatmentduringprimaryhivinfectionametaanalysis AT minghuian immunologicalandvirologicalbenefitsresultedfromshortcoursetreatmentduringprimaryhivinfectionametaanalysis AT jingliu immunologicalandvirologicalbenefitsresultedfromshortcoursetreatmentduringprimaryhivinfectionametaanalysis AT junjiexu immunologicalandvirologicalbenefitsresultedfromshortcoursetreatmentduringprimaryhivinfectionametaanalysis AT wenqinggeng immunologicalandvirologicalbenefitsresultedfromshortcoursetreatmentduringprimaryhivinfectionametaanalysis AT yangtaoji immunologicalandvirologicalbenefitsresultedfromshortcoursetreatmentduringprimaryhivinfectionametaanalysis AT hongshang immunologicalandvirologicalbenefitsresultedfromshortcoursetreatmentduringprimaryhivinfectionametaanalysis |